PALO ALTO, Calif. — May 5, 2026 — Leads & Copy — BridgeBio Pharma, Inc. (Nasdaq: BBIO) will share additional data regarding encaleret, from its Phase 3 CALIBRATE study in individuals with autosomal dominant hypocalcemia type 1 (ADH1). The data will be presented at the 2026 European Congress of Endocrinology (ECE) in Prague, Czech Republic, May 9-12, 2026.
The company will also share an additional oral presentation, one poster, and one eposter at the meeting.
Filomena Cetani, M.D., Ph.D., University of Pisa, IT, will present data on how Encaleret restores mineral homeostasis in ADH1, with primary results from the Phase 3 CALIBRATE Trial, on Tuesday, May 12 at 11:50 am CEST.
Arun Mathew, BridgeBio Endocrinology, U.S., will present data regarding genetic testing of over 400 individuals with non-surgical hypoparathyroidism that shows gain-of-function CASR variants as the most common genetic cause identified on Tuesday, May 12 at 12:20 pm CEST.
Heide Siggelkow, M.D., University Medical Center of Göttingen, DE, will present a poster on autosomal dominant hypocalcemia type 1 and type 2: Baseline quality of life measures in adult participants in the CLARIFY Disease Monitoring Study on Sunday, May 10 at 4:55 pm CEST and Monday, May 11 at 5 pm CEST. The Poster ID is P72.
Arun Mathew, BridgeBio Endocrinology, U.S., will present an ePoster on the epidemiology and clinical management of ADH1: A systematic literature review. The Poster ID is EP260.
BridgeBio develops transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. The company aims to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Its decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market.
Source: BridgeBio
